DNA-guided precision medicine for cancer: A case of irrational exuberance?

Abstract

Precision treatment with targeted cancer drugs requires the selection of patients who are most likely to benefit from a given therapy. We argue here that the use of a combination of both DNA and transcriptome analyses will significantly improve drug response prediction.